THERAPY DOSSIER · th-f2a1b80584f1

Recombinant angiopoietin-like 4 (ANGPTL4)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07164196 ↗Phase not recordedcompleted

Evaluation of Angiopoietin-like Protein 4 Levels in Patients With Endometriosis

Endometriosis · Angiopoietin-like Protein-4 · Pelvic Pain

Enrolment: 80 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23674618 ↗2013Reported benefit

Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6 (also angptl4-deficient mice)Male

Model: Transient middle cerebral artery occlusion (transient ischaemic stroke model)

Recombinant ANGPTL4 significantly decreased infarct size, preserved vascular network density and interendothelial junction integrity, reduced brain oedema and inflammation, prevented neuronal loss in the ischaemic area and improved behaviour. Angptl4-deficient mice showed increased vascular damage…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…